Pfizer Inc (PFE)

Cash ratio

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash and cash equivalents	US$ in thousands	1,043,000	2,853,000	416,000	1,944,000	1,784,000
Short-term investments	US$ in thousands	19,434,000	9,837,000	22,316,000	29,125,000	10,437,000
Total current liabilities	US$ in thousands	42,995,000	47,794,000	42,138,000	42,671,000	25,920,000
Cash ratio		0.48	0.27	0.54	0.73	0.47

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($1,043,000K + $19,434,000K) ÷ $42,995,000K
= 0.48

The cash ratio of Pfizer Inc has fluctuated over the past five years, ranging from 0.27 to 0.73. The ratio indicates the company's ability to cover its short-term liabilities with its cash and cash equivalents. In December 2021, the cash ratio improved significantly to 0.73, suggesting a stronger liquidity position. However, by December 2023, the ratio decreased to 0.27, signaling potential challenges in meeting short-term obligations with available cash. In the most recent year, December 2024, the cash ratio increased to 0.48, but it remains below the levels seen in 2021. Overall, Pfizer Inc should continue monitoring its cash position to ensure adequate liquidity to meet its financial commitments.